Histone deacetylase (HDAC) inhibitors have promising neuroprotective and anti-inflammatory properties although the exact mechanisms are unclear. We have earlier showed that factors from lipopolysaccharide (LPS)-activated microglia can down-regulate the astroglial nuclear factor-erythroid 2-related factor 2 (Nrf2)-inducible anti-oxidant defence. Here we have evaluated whether histone modification and activation of GSK3β are involved in these negative effects of microglia. Microglia were cultured for 24 h in serum-free culture medium to achieve microglia-conditioned medium from non-activated cells (MCM 0 ) or activated with 10 ng/mL of LPS to produce MCM 10 . Astrocyte-rich cultures treated with MCM 10 showed a time-dependent (0-72 h) increase in astroglial HDAC activity that correlated with lower levels of acetylation of histones H3 and H4 and decreased levels of the transcription factor Nrf2 and γ-glutamyl cysteine ligase modulatory subunit (γGCL-M) protein levels. The HDAC inhibitors valproic acid (VPA) and trichostatin-A (TSA) elevated the histone acetylation levels, restored the Nrf2-inducible anti-oxidant defence and conferred protection from oxidative stress-induced (H 2 O 2 ) death in astrocyte-rich cultures exposed to MCM 10 . Inhibitors of GSK3β (lithium) and p38 MAPK (SB203580) signaling pathways restored the depressed histone acetylation and Nrf2-related transcription whereas an inhibitor of Akt (Ly294002) caused a further decrease in Nrf2-related transcription. In conclusion, the study shows that well tolerated drugs such as VPA and lithium can restore an inflammatory induced depression in the Nrf2-inducible antioxidant defence, possibly via normalised histone acetylation levels.
Introduction
Acetylation of lysine residues in histones and other proteins such as transcription factors constitutes one important mean of regulation of transcription and gene expression (Chuang et al., 2009) . Histones acetyltransferases (HATs) and histones deacetylases (HDACs) constitute a group of enzymes that regulate acetylation/deacetylation. Inhibitors of HDACs are neuroprotective in several models of neurodegeneration (Chuang et al., 2009; Nalivaeva et al., 2009) . For example, trichostatin-A (TSA) protected neurons in an in vitro and in vivo model of oxidative stress induced by depletion of glutathione (GSH) (Ryu et al. 2003) . Likewise, astrocytes were less damaged by oxygen-glucose deprivation after TSA treatment via a reduced inflammatory reaction (Niu et al., 2009) . Another HDAC inhibitor, valproic acid (VPA) has been shown to protect neurons in culture from glutamate-induced excitotoxicity (Bown et al., 2003) . In a related study, it was shown that the effects of VPA were potentiated by simultaneous treatment with the glycogen synthase kinase-3 beta (GSK3β) inhibitor lithium (Leng et al., 2008; Adler et al., 2010) . In models of stroke, a decreased acetylation could be normalised with HDAC inhibitors which also resulted in a lower infarct volume in parallel with reduced inflammation (Kim et al., 2007) . Likewise, it has been shown that HDAC inhibitors reduce lippopolysaccharide (LPS)-induced release of pro-inflammatory cytokines in glial cells by a mechanism related to a reduced nuclear factor kappa-light-chainenhancer of activated B cells (NFκB)-induced transcription (Faraco et al., 2009 ).
Activation of microglia, i.e. neuroinflammation, is an important mechanism in brain defence but over-activation can cause and/or propagate neuronal damage in neurodegenerative diseases and Abbreviations: γGCL, gamma-glutamylcysteine ligase; γGCL-C, gamma-glutamylcysteine ligase catalytic subunit; γGCL-M, gamma-glutamylcysteine ligase modulatory subunit; GSH, glutathione; GSK3β, glycogen synthase kinase-3 beta; HAT, histone acetyltransferase; HDAC, histone deacetylase; Keap1, Kelch-like ECH-associated protein 1; ERK1/2, extracellular regulated kinase; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccaride; MAPKs, mitogenactivated protein kinases; MCM, microglia-conditioned medium; MEK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Nrf2, nuclear factor-erythroid 2-related factor 2; tBHQ, tert-butylhydroquinone; TSA, trichostatin A; VPA, valproic acid.
